Gad M. Gilad received his Ph.D. in neurobiology and behavior from Cornell University. His research focus is the response of the nervous system to stress, neurotrauma and neurodegenerative diseases (molecular mechanisms of nerve cell survival and death, and neuroplasticity), and the development of new therapeutics. His collaboration with Varda H. Gilad while working at several academic centers, including the National Institutes of Health, Weizmann Institute of Science and Harvard University, resulted in over 100 peer reviewed scientific papers and several patents. One of their main achievements is the discovery of the neuroprotective and neuro-rescue properties of agmatine and its development as a treatment for neuropathies and other diseases. He is the cofounder and CEO of Gilad&Gilad LLC, a health science company based in Georgetown, Texas. The Company develops and markets agmatine-based therapeutics.